Clinical Trial Update: Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction [Phase 4]

View source ↗

Summary

Phase 4 study evaluating safety, efficacy and treatment satisfaction when transitioning PAH patients from Ventavis (iloprost) to IV Remodulin (treprostinil); th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Remodulin (treprostinil)
• Ventavis (iloprost)

Snippet

Sponsor: United Therapeutics | Conditions: Hypertension, Pulmonary | Phase 4 | Status: TERMINATED